AMZN
Amazon.com, Inc.
AMZN has the edge over LEN-B overall, supported by stronger valuation and stronger modeled upside.
LEN-B
Lennar Corporation
LEN-B trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
LEN-B Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Strong |
LEN-B's balance sheet is currently strong, and its revenue, profitability and cash flow are stable.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over LEN-B in the historical PE scenario, which offers more potential upside but is not a forecast.
LEN-B PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.4x | $28.56 | -65% |
| Fair | 8.2x | $43.53 | -47% |
| Expensive | 11x | $57.92 | -29% |
| Current | 15x | $81.63 | — |
| Forward | 18x | $81.63 | — |
Historical ranges are pointers, not guarantees.
LEN-B's PE is in its expensive range at 15x. Analysts expect earnings to fall, which would put today's price at 18x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over LEN-B on the outlook, with more favorable earnings and revenue expectations.
LEN-B Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Decline | |
| Stable | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect LEN-B's earnings and profitability to decline, with its revenue holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over LEN-B on earnings, with more consistent year-over-year improvement.
LEN-B Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.59 | -13% |
| Q3 2026 | $5.28 | -48% |
| Q2 2026 | $6.38 | -47% |
| Q1 2026 | $6.95 | -49% |
| Q4 2025 | $7.98 | -44% |
| Q3 2025 | $10.09 | -33% |
| Q2 2025 | $12.06 | -18% |
| Q1 2025 | $13.70 | -3.8% |
| Q4 2024 | $14.31 | +4.2% |
LEN-B's earnings per share have fallen from their peak: $5.28 over the past year, against $16.09 in early 2023.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over LEN-B on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over LEN-B on profitability, with a higher operating margin.
LEN-B Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8B | -8.7% |
| Q2 2026 | $7.9B | -5.2% |
| Q1 2026 | $6.6B | -13% |
| Q4 2025 | $9.4B | -5.8% |
| Q3 2025 | $8.8B | -6.4% |
| Q2 2025 | $8.4B | -4.4% |
| Q1 2025 | $7.6B | +4.4% |
| Q4 2024 | $9.9B | -9.3% |
LEN-B's revenue has slid since its 2023 peak: $8B last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -2.2 points |
| Q2 2026 | 5% | -2.5 points |
| Q1 2026 | 3.3% | -5.8 points |
| Q4 2025 | 6.9% | -7.8 points |
| Q3 2025 | 7.9% | -5.7 points |
| Q2 2025 | 7.5% | -6.4 points |
| Q1 2025 | 9.1% | -3.2 points |
| Q4 2024 | 15% | -1.6 points |
LEN-B's operating margin was 5.7% last quarter, down 2.2 points from the same quarter a year ago, near the bottom of its range since 2019.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
LEN-B Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$96.3M | +$94.5M |
| Q2 2026 | -$303.2M | +$807M |
| Q1 2026 | -$463.5M | -$118.4M |
| Q4 2025 | $1.7B | +79% |
| Q3 2025 | -$190.8M | -124% |
| Q2 2025 | -$1.1B | -647% |
| Q1 2025 | -$345.1M | -217% |
| Q4 2024 | $933.1M | -63% |
LEN-B has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
LEN-B Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -3M shares |
| 1 year | -7% | -17.8M shares |
| 3 years | -16% | -45.1M shares |
| 5 years | -23% | -69.5M shares |
| Available history | -25% | -80.7M shares |
LEN-B has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $255.9M |
| Q2 2026 | $467.1M |
| Q1 2026 | $269.7M |
| Q4 2025 | $57,000 |
| Q3 2025 | $512.4M |
| Q2 2025 | $521.4M |
| Q1 2025 | $774.5M |
| Q4 2024 | $527.2M |
LEN-B spent $993M buying back its own shares over the past year, down 57% from the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
LEN-B Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -1.0x | Net Cash |
| Q4 2025 | 0.8x | Very low |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
LEN-B has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
LEN-B Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 70.3 | Neutral |
LEN-B's weekly RSI is 46 (neutral) and its Stochastic is 70 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
LEN-B PE vs Consumer Cyclical Sector
| Metric | LEN-B | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 18x | 14% below |
| PE % | 99 | 47 | 52 pts above |
LEN-B has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over LEN-B on trend strength, trading above more of its moving averages.
LEN-B Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $81.3 | 0.4% above |
| 20 week MA | $82.1 | 0.6% below |
| 50 week MA | $90.3 | 9.6% below |
| 100 week MA | $102.9 | 21% below |
| 200 week MA | $115.3 | 29% below |
LEN-B has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 29% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over LEN-B on returns for 2026, with the stronger performance.
LEN-B Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.9 | $64.4 | +44% |
| 2021 | $64.4 | $91.9 | +43% |
| 2022 | $91.9 | $75.1 | -18% |
| 2023 | $75.1 | $134.1 | +78% |
| 2024 | $134.1 | $133.3 | -0.6% |
| 2025 | $133.3 | $97.4 | -27% |
| 2026 YTD | $97.4 | $81.6 | -16% |
LEN-B has finished lower in three of the last six years. It's down 16% so far in 2026.